Khasar S G, McCarter G, Levine J D
Department of Medicine, Division of Neuroscience and Biomedical Sciences Program, National Institutes of Health Pain Center (UCSF), University of California, San Francisco, California 94143-0440, USA.
J Neurophysiol. 1999 Mar;81(3):1104-12. doi: 10.1152/jn.1999.81.3.1104.
Hyperalgesic and nociceptor sensitizing effects mediated by the beta-adrenergic receptor were evaluated in the rat. Intradermal injection of epinephrine, the major endogenous ligand for the beta-adrenergic receptor, into the dorsum of the hindpaw of the rat produced a dose-dependent mechanical hyperalgesia, quantified by the Randall-Selitto paw-withdrawal test. Epinephrine-induced hyperalgesia was attenuated significantly by intradermal pretreatment with propranolol, a beta-adrenergic receptor antagonist, but not by phentolamine, an alpha-adrenergic receptor antagonist. Epinephrine-induced hyperalgesia developed rapidly; it was statistically significant by 2 min after injection, reached a maximum effect within 5 min, and lasted 2 h. Injection of a more beta-adrenergic receptor-selective agonist, isoproterenol, also produced dose-dependent hyperalgesia, which was attenuated by propranolol but not phentolamine. Epinephrine-induced hyperalgesia was not affected by indomethacin, an inhibitor of cyclo-oxygenase, or by surgical sympathectomy. It was attenuated significantly by inhibitors of the adenosine 3',5'-cyclic monophosphate signaling pathway (the adenylyl cyclase inhibitor, SQ 22536, and the protein kinase A inhibitors, Rp-adenosine 3',5'-cyclic monophosphate and WIPTIDE), inhibitors of the protein kinase C signaling pathway (chelerythrine and bisindolylmaleimide) and a mu-opioid receptor agonist DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin). Consistent with the hypothesis that epinephrine produces hyperalgesia by a direct action on primary afferent nociceptors, it was found to sensitize small-diameter dorsal root ganglion neurons in culture, i. e., to produce an increase in number of spikes and a decrease in latency to firing during a ramped depolarizing stimulus. These effects were blocked by propranolol. Furthermore epinephrine, like several other direct-acting hyperalgesic agents, caused a potentiation of tetrodotoxin-resistant sodium current, an effect that was abolished by Rp-adenosine 3',5'-cyclic monophosphate and significantly attenuated by bisindolylmaleimide. Isoproterenol also potentiated tetrodotoxin-resistant sodium current. In conclusion, epinephrine produces cutaneous mechanical hyperalgesia and sensitizes cultured dorsal root ganglion neurons in the absence of nerve injury via an action at a beta-adrenergic receptor. These effects of epinephrine are mediated by both the protein kinase A and protein kinase C second-messenger pathways.
在大鼠中评估了由β-肾上腺素能受体介导的痛觉过敏和伤害感受器致敏作用。将β-肾上腺素能受体的主要内源性配体肾上腺素皮内注射到大鼠后爪背部,产生剂量依赖性的机械性痛觉过敏,通过Randall-Selitto爪撤离试验进行量化。皮内预先用β-肾上腺素能受体拮抗剂普萘洛尔预处理可显著减轻肾上腺素诱导的痛觉过敏,但α-肾上腺素能受体拮抗剂酚妥拉明则无此作用。肾上腺素诱导的痛觉过敏发展迅速;注射后2分钟具有统计学意义,5分钟内达到最大效应,并持续2小时。注射更具β-肾上腺素能受体选择性的激动剂异丙肾上腺素也产生剂量依赖性的痛觉过敏,该作用可被普萘洛尔减轻,但酚妥拉明无效。肾上腺素诱导的痛觉过敏不受环氧化酶抑制剂吲哚美辛或手术交感神经切除术的影响。它被腺苷3',5'-环磷酸信号通路抑制剂(腺苷酸环化酶抑制剂SQ 22536以及蛋白激酶A抑制剂Rp-腺苷3',5'-环磷酸和WIPTIDE)、蛋白激酶C信号通路抑制剂(白屈菜红碱和双吲哚马来酰胺)以及μ-阿片受体激动剂DAMGO([D-Ala2,N-Me-Phe4,Gly5-ol]-脑啡肽)显著减轻。与肾上腺素通过直接作用于初级传入伤害感受器产生痛觉过敏的假设一致,发现它可使培养的小直径背根神经节神经元致敏,即,在斜坡去极化刺激期间使动作电位数量增加且放电潜伏期缩短。这些作用被普萘洛尔阻断。此外,肾上腺素与其他几种直接作用的痛觉过敏剂一样,可增强河豚毒素抗性钠电流,该作用被Rp-腺苷3',5'-环磷酸消除,并被双吲哚马来酰胺显著减弱。异丙肾上腺素也增强河豚毒素抗性钠电流。总之,肾上腺素在无神经损伤的情况下通过作用于β-肾上腺素能受体产生皮肤机械性痛觉过敏并使培养的背根神经节神经元致敏。肾上腺素的这些作用由蛋白激酶A和蛋白激酶C第二信使通路介导。